Allergy Asthma Proc. 2024 Sep 1;45(5):321-325. doi: 10.2500/aap.2024.45.240057.
Specific antibody deficiency (SAD) is a common primary immunodeficiency disorder that should be considered in older children and adults with recurrent and/or severe sinopulmonary infections. The diagnosis is characterized by inadequate antibody response to polysaccharide vaccine, specifically, pneumococcal, with normal responses to protein antigens and normal levels of serum immunoglobulins as well as immunoglobulin G (IgG) subclasses. The underlying mechanism for SAD is not completely elucidated. It is understood that young children have limited polysaccharide responsiveness, which develops with increased age. Due to this phenomenon, the consensus is that there is adequate immune maturity after age 2 years, which is the earliest for the SAD diagnosis to be established. There remains a lack of consensus on thresholds for polysaccharide nonresponse, and there are several commercial laboratories that measure a range of serotypes, with the recommendation for patients to have their diagnostic evaluation with serotype testing both before vaccination and after vaccination to be conducted by the same laboratory. Once a diagnosis has been made, the management of SAD is based on the clinical severity. Clinicians may consider prophylactic antibiotics as well as immunoglobulin replacement. These patients should be closely followed up, with the possibility of discontinuation of IgG replacement after 12 to 24 months. Children are more likely to demonstrate resolution of SAD than are adolescents and adults. Patients with SAD may also progress to a more severe immunodeficiency; therefore, continued monitoring remains a crucial principle of practice in the care of patients with SAD.
特定抗体缺陷症(SAD)是一种常见的原发性免疫缺陷疾病,应考虑在反复发生和/或严重的鼻窦和肺部感染的大龄儿童和成人中进行诊断。该疾病的诊断特征为对多糖疫苗(尤其是肺炎球菌疫苗)的抗体反应不足,但对蛋白质抗原的抗体反应正常,血清免疫球蛋白以及免疫球蛋白 G(IgG)亚类的水平也正常。SAD 的潜在发病机制尚未完全阐明。据了解,儿童对多糖的反应能力有限,随着年龄的增长而逐渐增强。由于这种现象,人们普遍认为 2 岁以后免疫成熟度足够,这是确立 SAD 诊断的最早时间。对于多糖无反应的阈值,目前仍缺乏共识,并且有几家商业实验室可测量多种血清型,建议患者在接种疫苗前后在同一家实验室进行血清型检测,以进行诊断评估。一旦确诊,SAD 的管理基于临床严重程度。临床医生可能会考虑预防性使用抗生素和免疫球蛋白替代治疗。应对这些患者进行密切随访,在 12 至 24 个月后可能会停止 IgG 替代治疗。与青少年和成年人相比,儿童更有可能痊愈。SAD 患者也可能进展为更严重的免疫缺陷;因此,持续监测仍然是 SAD 患者护理实践中的关键原则。